{
  "as_of": "2026-11-03",
  "track": "ipsc-stem-cell",
  "source_url": "https://drugnews.com.tw/en/asia-ipsc-stem-cell-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "RiHEART",
      "Not disclosed",
      "Cuorips Inc. (Osaka University / Daiichi Sankyo technology)",
      "Japan",
      "Ischaemic myocardium",
      "Allogeneic iPSC-derived cardiomyocyte patch; intended paracrine support of myocardial function",
      "Approved — Japan (2026-03; conditional and time-limited)",
      "Severe heart failure due to ischaemic cardiomyopathy refractory to standard pharmacological/invasive therapy",
      "NCT04696328",
      "None reported",
      "—",
      "—",
      "—",
      "Japan conditional and time-limited marketing authorisation granted",
      "2026-03-06",
      "https://www.cuorips.co.jp/en/riheart | https://www.mhlw.go.jp/web/t_doc?dataId=00tc9802&dataType=1&pageNo=1 | https://www.cuorips.co.jp/en/company | https://clinicaltrials.gov/study/NCT04696328",
      "2026-11-03"
    ],
    [
      "2",
      "AMCHEPRY",
      "raguneprocel",
      "Sumitomo Pharma / RACTHERA (Kyoto University technology)",
      "Japan",
      "Dopaminergic neuronal loss",
      "Allogeneic iPSC-derived dopaminergic neural progenitor cell therapy",
      "Approved — Japan (2026-03; conditional and time-limited)",
      "Parkinson disease motor symptoms inadequately controlled by existing therapies including levodopa",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "Japan conditional and time-limited marketing authorisation granted",
      "2026-03-06",
      "https://www.sumitomo-pharma.com/news/20260306.html | https://www.mhlw.go.jp/web/t_doc?dataId=00tc9802&dataType=1&pageNo=1 | https://clinicaltrials.gov/",
      "2026-11-03"
    ],
    [
      "3",
      "AKUUGO (SB623)",
      "vandefitemcel",
      "SanBio Company Limited",
      "Japan",
      "Chronic traumatic brain injury motor deficits",
      "Modified allogeneic bone-marrow MSC therapy; proposed cytokine-mediated neural repair",
      "Approved — Japan (2024-07; conditional and time-limited)",
      "Improvement of chronic motor paralysis associated with traumatic brain injury",
      "NCT02416492",
      "None reported",
      "—",
      "—",
      "—",
      "SanBio announced first post-marketing administration of AKUUGO",
      "2026-10-07",
      "https://www.sanbio.com/en/ir/message/ | https://www.pmda.go.jp/files/000275128.pdf | https://www.sanbio.com/pdf/news/news_20261007.pdf | https://www.sanbio.com/en/about/overview/ | https://clinicaltrials.gov/study/NCT02416492",
      "2026-11-03"
    ],
    [
      "4",
      "STEMIRAC",
      "Not disclosed",
      "Nipro Corporation / Sapporo Medical University",
      "Japan",
      "Traumatic spinal cord injury",
      "Autologous bone-marrow mesenchymal stem cell therapy",
      "Approved — Japan (2018-12; conditional and time-limited; full-approval panel endorsement 2026-10)",
      "Spinal cord injury",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "Panel endorsed full approval on 2026-10-15; source says formal ministerial approval still expected",
      "2026-10-15",
      "https://web.sapmed.ac.jp/regeneration/topics/2026/c7d4lo000000005c.html | https://www.nipro.co.jp/en/corporate/profile/ | https://clinicaltrials.gov/",
      "2026-11-03"
    ],
    [
      "5",
      "NEURONATA-R",
      "lenzumestrocel",
      "CorestemChemon Inc.",
      "South Korea",
      "ALS-associated motor-neuron injury / neuroinflammation",
      "Autologous bone-marrow MSC therapy with immunomodulatory/neurotrophic rationale",
      "Approved — South Korea (2014-07; conditional; continued use approved 2026-05)",
      "Delaying ALS progression, with riluzole",
      "NCT04745299",
      "None reported",
      "—",
      "—",
      "—",
      "Issuer reports May 2026 licence modification retaining conditional access; manufacturing restart planned",
      "2026-07-20",
      "https://en.prnasia.com/releases/global/neuronata-r-retains-conditional-approval-in-south-korea-541158.shtml | https://www.corestemchemon.com/eng/business/business__product.html | https://clinicaltrials.gov/study/NCT04745299",
      "2026-11-03"
    ],
    [
      "6",
      "Cupistem",
      "Not disclosed",
      "Anterogen Co., Ltd.",
      "South Korea",
      "Crohn disease-associated fistula",
      "Adipose-derived stem cell therapy",
      "Approved — South Korea (2012-01)",
      "Crohn disease fistula",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "Korean marketing authorisation obtained (historical approval; no newer asset-specific event established)",
      "2012-01",
      "https://anterogen.com/main/en/sub01_01.html?type=1 | https://clinicaltrials.gov/",
      "2026-11-03"
    ],
    [
      "7",
      "CARTISTEM",
      "Not disclosed",
      "MEDIPOST Co., Ltd.",
      "South Korea",
      "Osteoarthritic knee cartilage defects",
      "Allogeneic umbilical cord blood-derived MSC therapy",
      "Approved — South Korea (2012-01)",
      "ICRS grade IV knee cartilage defects associated with degeneration or repetitive trauma",
      "NCT07339111",
      "Teikoku Seiyaku (exclusive Japan sales/distribution/promotion); MEDIPOST retains manufacturing",
      "2025-12-19",
      "USD 8m",
      "Not disclosed (USD 10m regulatory milestone; sales milestones undisclosed)",
      "First US participant treated in Phase 3; Korean approval and Japan Phase 3 completion are separate milestones",
      "2026-07-07",
      "https://en.medi-post.co.kr/cartistem/ | https://en.medi-post.co.kr/stem-cell-therapeutic/2026/07/38349/ | https://en.medi-post.co.kr/intro/ | https://www.prnewswire.com/apac/news-releases/medipost-announces-the-exclusive-commercialization-license-agreement-with-teikoku-seiyaku-for-knee-osteoarthritis-treatment-cartistem-in-japan-302646496.html | https://clinicaltrials.gov/study/NCT07339111",
      "2026-11-03"
    ],
    [
      "8",
      "Hearticellgram-AMI",
      "Not disclosed",
      "Pharmicell Co., Ltd.",
      "South Korea",
      "Post-infarction left-ventricular dysfunction",
      "Autologous bone-marrow MSC therapy for cardiac functional recovery",
      "Approved — South Korea (2011-07)",
      "Improving left-ventricular ejection fraction after acute myocardial infarction",
      "NCT01652209",
      "None reported",
      "—",
      "—",
      "—",
      "Korean approval recorded by MFDS (historical approval; no newer asset-specific event established)",
      "2011-07",
      "https://mfds.go.kr/eng/brd/m_30/view.do?itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&page=1&seq=70957 | https://pharmicell.com/biz/medicine_cellgram.php | https://clinicaltrials.gov/study/NCT01652209",
      "2026-11-03"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://www.cuorips.co.jp/en/riheart",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.mhlw.go.jp/web/t_doc?dataId=00tc9802&dataType=1&pageNo=1",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.cuorips.co.jp/en/company",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04696328",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://www.sumitomo-pharma.com/news/20260306.html",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.mhlw.go.jp/web/t_doc?dataId=00tc9802&dataType=1&pageNo=1",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://www.sanbio.com/en/ir/message/",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.pmda.go.jp/files/000275128.pdf",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.sanbio.com/pdf/news/news_20261007.pdf",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.sanbio.com/en/about/overview/",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT02416492",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://web.sapmed.ac.jp/regeneration/topics/2026/c7d4lo000000005c.html",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.nipro.co.jp/en/corporate/profile/",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://en.prnasia.com/releases/global/neuronata-r-retains-conditional-approval-in-south-korea-541158.shtml",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.corestemchemon.com/eng/business/business__product.html",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04745299",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://anterogen.com/main/en/sub01_01.html?type=1",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://en.medi-post.co.kr/cartistem/",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://en.medi-post.co.kr/stem-cell-therapeutic/2026/07/38349/",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://en.medi-post.co.kr/intro/",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://www.prnewswire.com/apac/news-releases/medipost-announces-the-exclusive-commercialization-license-agreement-with-teikoku-seiyaku-for-knee-osteoarthritis-treatment-cartistem-in-japan-302646496.html",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07339111",
        "source_date": "2026-11-03"
      }
    ],
    [
      {
        "url": "https://mfds.go.kr/eng/brd/m_30/view.do?itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&page=1&seq=70957",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://pharmicell.com/biz/medicine_cellgram.php",
        "source_date": "2026-11-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT01652209",
        "source_date": "2026-11-03"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "RiHEART",
      "inn": "Not disclosed",
      "originator": "Cuorips Inc. (Osaka University / Daiichi Sankyo technology)",
      "country": "Japan",
      "target": "Ischaemic myocardium",
      "mechanism": "Allogeneic iPSC-derived cardiomyocyte patch; intended paracrine support of myocardial function",
      "highest_stage": "Approved — Japan (2026-03; conditional and time-limited)",
      "indications": "Severe heart failure due to ischaemic cardiomyopathy refractory to standard pharmacological/invasive therapy",
      "trial_ids": "NCT04696328",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Japan conditional and time-limited marketing authorisation granted",
      "latest_event_date": "2026-03-06",
      "source_urls": "https://www.cuorips.co.jp/en/riheart | https://www.mhlw.go.jp/web/t_doc?dataId=00tc9802&dataType=1&pageNo=1 | https://www.cuorips.co.jp/en/company | https://clinicaltrials.gov/study/NCT04696328",
      "source_date": "2026-11-03"
    },
    {
      "rank": "2",
      "asset": "AMCHEPRY",
      "inn": "raguneprocel",
      "originator": "Sumitomo Pharma / RACTHERA (Kyoto University technology)",
      "country": "Japan",
      "target": "Dopaminergic neuronal loss",
      "mechanism": "Allogeneic iPSC-derived dopaminergic neural progenitor cell therapy",
      "highest_stage": "Approved — Japan (2026-03; conditional and time-limited)",
      "indications": "Parkinson disease motor symptoms inadequately controlled by existing therapies including levodopa",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Japan conditional and time-limited marketing authorisation granted",
      "latest_event_date": "2026-03-06",
      "source_urls": "https://www.sumitomo-pharma.com/news/20260306.html | https://www.mhlw.go.jp/web/t_doc?dataId=00tc9802&dataType=1&pageNo=1 | https://clinicaltrials.gov/",
      "source_date": "2026-11-03"
    },
    {
      "rank": "3",
      "asset": "AKUUGO (SB623)",
      "inn": "vandefitemcel",
      "originator": "SanBio Company Limited",
      "country": "Japan",
      "target": "Chronic traumatic brain injury motor deficits",
      "mechanism": "Modified allogeneic bone-marrow MSC therapy; proposed cytokine-mediated neural repair",
      "highest_stage": "Approved — Japan (2024-07; conditional and time-limited)",
      "indications": "Improvement of chronic motor paralysis associated with traumatic brain injury",
      "trial_ids": "NCT02416492",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "SanBio announced first post-marketing administration of AKUUGO",
      "latest_event_date": "2026-10-07",
      "source_urls": "https://www.sanbio.com/en/ir/message/ | https://www.pmda.go.jp/files/000275128.pdf | https://www.sanbio.com/pdf/news/news_20261007.pdf | https://www.sanbio.com/en/about/overview/ | https://clinicaltrials.gov/study/NCT02416492",
      "source_date": "2026-11-03"
    },
    {
      "rank": "4",
      "asset": "STEMIRAC",
      "inn": "Not disclosed",
      "originator": "Nipro Corporation / Sapporo Medical University",
      "country": "Japan",
      "target": "Traumatic spinal cord injury",
      "mechanism": "Autologous bone-marrow mesenchymal stem cell therapy",
      "highest_stage": "Approved — Japan (2018-12; conditional and time-limited; full-approval panel endorsement 2026-10)",
      "indications": "Spinal cord injury",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Panel endorsed full approval on 2026-10-15; source says formal ministerial approval still expected",
      "latest_event_date": "2026-10-15",
      "source_urls": "https://web.sapmed.ac.jp/regeneration/topics/2026/c7d4lo000000005c.html | https://www.nipro.co.jp/en/corporate/profile/ | https://clinicaltrials.gov/",
      "source_date": "2026-11-03"
    },
    {
      "rank": "5",
      "asset": "NEURONATA-R",
      "inn": "lenzumestrocel",
      "originator": "CorestemChemon Inc.",
      "country": "South Korea",
      "target": "ALS-associated motor-neuron injury / neuroinflammation",
      "mechanism": "Autologous bone-marrow MSC therapy with immunomodulatory/neurotrophic rationale",
      "highest_stage": "Approved — South Korea (2014-07; conditional; continued use approved 2026-05)",
      "indications": "Delaying ALS progression, with riluzole",
      "trial_ids": "NCT04745299",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Issuer reports May 2026 licence modification retaining conditional access; manufacturing restart planned",
      "latest_event_date": "2026-07-20",
      "source_urls": "https://en.prnasia.com/releases/global/neuronata-r-retains-conditional-approval-in-south-korea-541158.shtml | https://www.corestemchemon.com/eng/business/business__product.html | https://clinicaltrials.gov/study/NCT04745299",
      "source_date": "2026-11-03"
    },
    {
      "rank": "6",
      "asset": "Cupistem",
      "inn": "Not disclosed",
      "originator": "Anterogen Co., Ltd.",
      "country": "South Korea",
      "target": "Crohn disease-associated fistula",
      "mechanism": "Adipose-derived stem cell therapy",
      "highest_stage": "Approved — South Korea (2012-01)",
      "indications": "Crohn disease fistula",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Korean marketing authorisation obtained (historical approval; no newer asset-specific event established)",
      "latest_event_date": "2012-01",
      "source_urls": "https://anterogen.com/main/en/sub01_01.html?type=1 | https://clinicaltrials.gov/",
      "source_date": "2026-11-03"
    },
    {
      "rank": "7",
      "asset": "CARTISTEM",
      "inn": "Not disclosed",
      "originator": "MEDIPOST Co., Ltd.",
      "country": "South Korea",
      "target": "Osteoarthritic knee cartilage defects",
      "mechanism": "Allogeneic umbilical cord blood-derived MSC therapy",
      "highest_stage": "Approved — South Korea (2012-01)",
      "indications": "ICRS grade IV knee cartilage defects associated with degeneration or repetitive trauma",
      "trial_ids": "NCT07339111",
      "overseas_rights_holder": "Teikoku Seiyaku (exclusive Japan sales/distribution/promotion); MEDIPOST retains manufacturing",
      "deal_date": "2025-12-19",
      "upfront": "USD 8m",
      "total_value": "Not disclosed (USD 10m regulatory milestone; sales milestones undisclosed)",
      "latest_event": "First US participant treated in Phase 3; Korean approval and Japan Phase 3 completion are separate milestones",
      "latest_event_date": "2026-07-07",
      "source_urls": "https://en.medi-post.co.kr/cartistem/ | https://en.medi-post.co.kr/stem-cell-therapeutic/2026/07/38349/ | https://en.medi-post.co.kr/intro/ | https://www.prnewswire.com/apac/news-releases/medipost-announces-the-exclusive-commercialization-license-agreement-with-teikoku-seiyaku-for-knee-osteoarthritis-treatment-cartistem-in-japan-302646496.html | https://clinicaltrials.gov/study/NCT07339111",
      "source_date": "2026-11-03"
    },
    {
      "rank": "8",
      "asset": "Hearticellgram-AMI",
      "inn": "Not disclosed",
      "originator": "Pharmicell Co., Ltd.",
      "country": "South Korea",
      "target": "Post-infarction left-ventricular dysfunction",
      "mechanism": "Autologous bone-marrow MSC therapy for cardiac functional recovery",
      "highest_stage": "Approved — South Korea (2011-07)",
      "indications": "Improving left-ventricular ejection fraction after acute myocardial infarction",
      "trial_ids": "NCT01652209",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Korean approval recorded by MFDS (historical approval; no newer asset-specific event established)",
      "latest_event_date": "2011-07",
      "source_urls": "https://mfds.go.kr/eng/brd/m_30/view.do?itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&page=1&seq=70957 | https://pharmicell.com/biz/medicine_cellgram.php | https://clinicaltrials.gov/study/NCT01652209",
      "source_date": "2026-11-03"
    }
  ]
}